PubMed Health⌕ Search

Biomedical subjects

M A Morozova

Publications and source records attributed to M A Morozova.

16 recordsLinked to original sources
PubMed2004

[A change of immune profile of patients with schizophrenia during treatment].

Cellular and humoral immunological parameters have been studied in 59 schizophrenic patients and 38 healthy controls. Immunological indices (CIC, autoantibodies to cardiolipin) were found to be significantly elevated in patients in the acute disease stage before the treatment. After olanzapin therapy, a level of these parameters decreased and did not differ from that of controls. In patients, irrespective of clinical condition and treatment, functional activity of immunocompetent cells (phagocyte activity of neutrophils and monocytes, cytotoxic activity of lymphocytes natural killers, interleukin-2, interleukin-10 and gamma-interferon production), was significantly lower both before the treatment as after therapy, i.e. did not change during the whole study (28 weeks). In responders, a level of IL-1B production was higher than in controls before and during the treatment. In non-responders, it was similar to that in controls before the therapy, and increased during the treatment to a higher level.

Acute Disease↗
PubMed2004

[Preventive efficacy of tianeptine in recurrent depression with frequent exacerbations].

The results of the studies of 4 Russian research centers are summarized. Tianeptine (coaxil) was used in the treatment of 55 patients with ICD-10 diagnosis of recurrent depressive disorder (F32.1), 50 patients have completely finished the treatment. Tianeptine was assigned in dosage of 12.5 mg 3 times daily (patients over 65 years old received 25.0 mg daily) during 12 months. The drug was shown to have a high preventive efficacy for the disorder. Sixty-one percent of patients were full-responders. Taken together with partial responders (13%), an improvement was observed in 74% patients. The drug demonstrated a well tolerability with a rare and mild expression of side-effects.

Adult↗
PubMed2003

[Age dynamics of temporal lobe epilepsy in children].

To study clinical features of temporal lobe epilepsy in children of different age, to trace disease development and to define risk factors for its occurrence and adverse course, 88 patients aged 3-14 years were examined. The study confirmed that temporal lobe epilepsy has its characteristic clinical features in children of different age. In children under 7 years of age, motor and autonomic paroxysms prevail accompanied in older children with psychomotor and psychosensory fits. With age the latter become more complicated. In children under 10 years of age psychomotor seizures prevail and in those older 10 years sensory and psychosensory ones predominate. Children over 10 years were characterized by polymorphic seizures or combinations of several kinds of seizures. The seizures can transform into either generalized or focal ones. In our study, the course of temporal lobe epilepsy was rather favorable. Seizures number reduced by more than a half in 82% of the cases. Adverse disease course was mainly detected in children with perinatal complications in their anamnesis and "spike-wave" complexes in EEG as well as in those suffering from psychomotor and psychosensory seizures.

Adolescent↗
PubMed2003

[Structural-dynamic analysis of the mechanism of clinical response and treatment prognosis].

The paper presents the results of testing of a new approach to study the inter-syndrome links in initial and follow up status of patients treated with atypical antipsychotics and to determine a system of prognostic clinical factors. The method, named structural-dynamic analysis, is based on comparison of initial and final structure of patient's condition grouped by the features of dynamics of its separate elements. These elements are chosen in accordance to PANSS and the grouping, therefore, is performed 30 times. The subject of the study was a sample of 89 patients with acute exacerbation of schizophrenia with intermittent course treated with atypical antipsychotic as monotherapy. The results of the study demonstrated that the new approach was informative and allowed to elucidate the most important parts of patient's condition, changes of which served as a basis for alterations in many other aspects of clinical status and consequently could be determined as the main characteristics of treatment efficacy. At the same time, these parts not in all the cases define the features of the clinical picture, being overlapped by the more striking symptoms. However, changes of the latter much less reflect the global changes in biological processes influenced by antipsychotics.

Acute Disease↗
PubMed2003

[Clinical efficacy and tolerability of tianeptine in treatment of depression (Russian open multicenter trial)].

One hundred and forty two patients with ICD-10 diagnosis of depression from 7 research scientific were treated with tianeptine (coaxil); 124 have completed the treatment course. Moderate depression was diagnosed in 111 patients (89.5%) and severe depression--in 13 (10.5%). A duration of the last episode before treatment was 7.1 +/- 1.7 months. The mean score by Hamilton depression scale was 24.4 +/- 4.0. The patients received tianeptine as a monotherapy in dosage 12.5 mg, 3 times daily during 6 weeks (65-year olds and older were given 25 mg daily). Tianeptine proved to be an antidepressant with balanced action, i.e., exerted thymoanaleptic, anxiolytic and activating effects. The treatment was beneficial for 70.4% of the patients; remission was revealed in 58%. The medication was well tolerated with rare and weakly pronounced side effects.

Adult↗
PubMed2001

[Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies].

Polyclonal (PAb) and monoclonal (MAb) antibodies to CT2-epitope of the C-terminal fragment of serotonin transporter (SERT) protein were used to study the levels and molecular heterogeneity of platelet SERT in healthy donors and patients with affective (AD) and somatoform (SD) disorders, schizoaffective disorder (SAD) and schizophrenia. SERT was found to exist as high molecular wight (HMW) and low molecular weight (LMW) forms separated after electrophoresis. The levels of HMW and LMW forms of SERT were significantly, decreased in mentally ill patients as compared to healthy individuals. Unlike PAb, horse radish peroxidase (HRP)-conjugated MAbs were more sensitive and specific to SERT and could detect the LMW form of SERT as a duplet protein form with MW about 40 and 43 kDa. The MAb to CT2 C-terminal fragment of SERT conjugated with HRP is considered to be a new valuable tool for further investigation of SERT expression, properties, and posttranslation modification in the controls and in patients with different psychopathology.

Adult↗
PubMed2000

[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].

Thirty adult patients with acute schizophrenia were included into six-week open-labelled, non-comparative trial of olanzapine with free dosing from 5 to 20 mg per day. For assessment of efficacy and safety of the treatment PANSS, BPRS, CGL and ESRS scales were used. The main criterion of improvement was the percentage of reduction of BPRS score to the end of the trial. More than 50% reduction was achieved in 23% of the patients, more than 20%--in 57% of the cases; 20% were non-responders (reduction less than 20%). Changes in the scores of the positive and negative PANSS subscales were significant (p < 0.001) starting from the second week of treatment. There was no correlation in changes in positive and negative scores as well as in changes in negative and ESRS scores. The first signs of the antipsychotic effect (a reduction of tension, suspiciousness and fear) appeared just in the first two weeks of treatment and manifested in the reduction of delusions and hallucinations. Reduction of depression didn't correlate with changes in scores of the positive or negative PANSS subscales. The changes in behavioral and cognitive symptoms were statistically significant starting from the second week of treatment. No clinically significant signs of extrapiramidal syndrome or other side-effects except weight gain were observed during the trial.

Acute Disease↗
PubMed1999

[The status of serotonin protein -- a serotonin transporter in thrombocytes in patients with somatoform disorders].

The role of serotonin transporter (SERT) protein in the development of somatoform disorders (SD) was investigated. An association study was performed in terms of the evaluation of the level of SERT immunoreactive (IR-SERT) protein using site-specific antibodies directed at SERT C-terminus fragment, poorly conserved among the other cotransporters. The level of the anxious symptomatology was also estimated in the patients with SD. 22 patients, who met DSM-IV criteria for somatoform disorders, and 32 normals were examined. In platelets from normals, IR-SERT protein migrated as a difuse band between 68 and 105 kDa, and a major sharper band at 43 kDa. Almost complete disappearance of platelet 43 kDa IR-SERT protein band was observed in most of the patients with SD. These findings permitted to suggest a possibility of either biosynthetic or processing abnormality of SERTs in the affected population, that might reflect a dysfunction of serotonin neurotransmission in CNS of the patients with SD.

Adult↗
PubMed1997

[Effect of thymoleptics in aspects of new clinical systematics of depressive syndrome].

Analysis of present concepts of clinico-pharmacological correlations in depression shows the necessity of search for new approaches to the problem. The original clinical model of depression, based on the idea of positive and negative affectivity in its structure is discussed. When applied to therapeutical strategy these principals elucidate new clinical signs for choice of appropriate class of antidepressants. The correlation between predominance of positive or negative appearance of depression and efficacy of antidepressants with selective and non-selective neurochemical action is suggested. A new clinical classification of antidepressants based on their influence on the negative or positive appearance of affective disorder is suggested. The speculations on certain neurochemical specificity of negative and positive disorders are presented.

Antidepressive Agents↗
PubMed1989

[Clinical characteristics of endogenous affective psychoses with predominantly manic conditions].

Clinico-catamnestic method was applied to the study of 48 patients with endogenous affective psychosis with prevalent manic disorders. Three forms of the disease are described which differ in a range of clinical and pathological signs. The differences in the conditions under which these forms develop suggest that these are leading pathogenic mechanisms exerting a pathoplastic effect on the clinical picture of manifest manic disorders. Some of these parameters as the peculiarities of premanifest stage, clinical type and the course of manifest manic phases can be safely taken as predictors of the course of affective psychosis with preponderance of manic disorders.

Adolescent↗
PubMedDate not supplied

The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders.

The role of the serotonin transporter protein (STP) in the development of somatoform [corrected] disorders was addressed in a correlational study of the levels of immunoreactive STP (IR-STP) using site-specific antibodies against the least conserved (among a group of other cotransporters) epitope at the C-terminal of STP and the level of anxiety symptoms in patients with somatoform [corrected] disorders. A total of 22 patients were studied, with DSM-IV diagnoses of somatoform [corrected] disorders, along with 32 mentally healthy subjects of comparable age and sex. Immunoblotting of IR-STP from patients from healthy donors produced a diffuse band between 68 and 105 kDal and a clear narrow band at 43 kDal. The 43-kDal IR-STP protein was almost completely absent from most patients, as compared with the levels of this protein in healthy donors. This result suggests an abnormality of STP processing or, perhaps, alternative splicing of the gene encoding STP in patients with somatoform [corrected] disorders, and this appears to reflect the dysfunction in serotoninergic transmission in the CNS in these patients.

Adult↗
PubMedDate not supplied

[Decrease in the platelet level of 43 kDa immunoreactive fraction of serotonin transporting protein correlates with depressive symptoms in patients with somatoform disorders].

To elucidate the role of serotonin transporter (SERT) protein as a candidate target for somatoform disorders (SD), we have performed an association study of the SERT immunoreactive (IR-SERT) protein level by using site-specific antibodies directed at C-terminus epitope poorly conserved among other cotransporters. 22 patients who met DSM-IY criteria for SD and 32 healthy volunteers matched in sex and age participated in the study. In platelets from all healthy donors, IR-SERT proteins migrates as a diffuse band between 75 and 102 kDa and a major sharper band at 43 kDa. We revealed almost complete disappearance of platelet 43 kDa IR-SERT protein in all patients with SD. All patients were rated with Hamilton Depressive Rating Scale (HDRS). There were found a significant negative correlation between residual IR-SERT 43 kDa protein level and HDRS Scores [r = -0.83; P < 0.000001]. These findings suggest that a biosynthetic or processing abnormality may exist in SERTs in the affected population and may reflect the dysfunction of serotonin neurotransmission in CNS.

Adult↗